Post-traumatic stress disorder: Emerging concepts of pharmacotherapy

Expert Opinion on Emerging Drugs

Volumn 14, Issue 2, 2009, Pages 251-272

  Baker, Dewleen G ^a,b   Nievergelt, Caroline M ^a   Risbrough, Victoria B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Antidepressants; Antipsychotics; Benzodiazepines; Fear extinction; Glutamate; Post traumatic stress disorder; Serotonin reuptake inhibitors

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; BROFAROMINE; CITALOPRAM; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; GUANFACINE; HON 0001; HYDROCORTISONE; KETAMINE; LAMOTRIGINE; LY 35450; MIFEPRISTONE; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENELZINE; PRAZOSIN; RISPERIDONE; SELEGILINE; SERTRALINE; TALAGLUMETAD; TIAGABINE; TOPIRAMATE; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VOFOPITANT;

AKATHISIA; AMYGDALOID NUCLEUS; ANXIETY DISORDER; BIPOLAR DISORDER; BLOOD PRESSURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIPLOPIA; DISTRESS SYNDROME; DIZZINESS; DRUG EFFICACY; DRUG STRUCTURE; DYSTHYMIA; EPIGENETICS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEADACHE; HEART RATE; HUMAN; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; INTRAOCULAR PRESSURE; MAJOR DEPRESSION; MENTAL HEALTH; NAUSEA; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PSYCHOSIS; PSYCHOTHERAPY; REM SLEEP; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYNCOPE; TARDIVE DYSKINESIA; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG DELIVERY SYSTEMS; HUMANS; PSYCHOTROPIC DRUGS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 67649386619     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210902972494     Document Type: Review

References (206)

1. Homer. The Iliad: The Fitzgerald Translation: Farrar, Straus and Giroux, 2004
2. Janet P. Psychological healing; a historical and clinical study. London: G. Allen & Unwin Ltd.; New York, The Macmillan company, 1925
3. van der Kolk BA, van der Hart O. Pierre Janet and the breakdown of adaptation in psychological trauma. Am J Psychiatry 1989;146(12):1530-1540 (Pubitemid 20014722)
4. APA. section 309.81: Posttraumatic stress disorder. Diagnostic and statistical manual of mental disorders : DSM-IV-TR. 4 edition. Washington, DC: American Psychiatric Association, 2000
5. Creamer M, Burgess P, McFarlane AC. Post-traumatic stress disorder: findings from the Australian national survey of mental health and well-being. Psychol Med 2001;31(7):1237-1247 (Pubitemid 32975889)
6. Baker DG, Diamond BI, Gillette G, et al. A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology (Berl) 1995;122(4):386-389 (Pubitemid 26011419)
7. Breslau N, Davis GC, Andreski P, Peterson E. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry 1991;48(3):216-222
8. Frans O, Rimmo PA, Aberg L, Fredrikson M. Trauma exposure and post-traumatic stress disorder in the general population. Acta Psychiatr Scand 2005;111(4):291-299 (Pubitemid 40445034)
9. Darves-Bornoz JM, Alonso J, de Girolamo G, et al. Main traumatic events in Europe: PTSD in the European study of the epidemiology of mental disorders survey. J Trauma Stress 2008;21(5):455-462
10. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 109(420):21-27 (Pubitemid 38686193)
11. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry 1995;52(12):1048-1060
12. Perkonigg A, Kessler RC, Storz S, Wittchen HU. Traumatic events and post-traumatic stress disorder in the community: prevalence, risk factors and comorbidity. Acta Psychiatr Scand 2000;101(1):46-59 (Pubitemid 30041123)
13. Norris FH, Murphy AD, Baker CK, et al. Epidemiology of trauma and posttraumatic stress disorder in Mexico. J Abnorm Psychol 2003;112(4):646-656 (Pubitemid 37509610)
14. Green BL, Grace MC, Lindy JD, et al. Risk factors for PTSD and other diagnoses in a general sample of Vietnam veterans. Am J Psychiatry 1990;147(6):729-733 (Pubitemid 20188511)
15. Wolfe J, Chrestman KR, Ouimette PC, et al. Trauma-related psychophysiological reactivity in women exposed to war-zone stress. J Clin Psychol 2000;56(10):1371-1379 (Pubitemid 30757353)
16. Stein MB, Jang KL, Taylor S, et al. Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms: a twin study. Am J Psychiatry 2002;159(10):1675-1681
17. Shalev AY, Freedman S. PTSD following terrorist attacks: a prospective evaluation. Am J Psychiatry 2005;162(6):1188-1191 (Pubitemid 40770703)
18. Van Ameringen M, Mancini C, Patterson B, Boyle MH. Post-traumatic stress disorder in Canada. CNS Neurosci Ther 2008 Fall;14(3):171-181
19. North CS, Pfefferbaum B, Narayanan P, et al. Comparison of post-disaster psychiatric disorders after terrorist bombings in Nairobi and Oklahoma City. Br J Psychiatry 2005;186:487-493 (Pubitemid 40834868)
20. North CS, Suris AM, Davis M, Smith RP. Toward validation of the diagnosis of posttraumatic stress disorder. Am J Psychiatry 2009;166(1):34-41
21. Kessler RC, Wang PS. The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 2008;29:115-129 (Pubitemid 351600402)
22. Tanios CY, Abou-Saleh MT, Karam AN, et al. The epidemiology of anxiety disorders in the Arab world: a review. J Anxiety Disord 2008;23(4):409-419
23. Fernando GA. Assessing mental health and psychosocial status in communities exposed to traumatic events: Sri Lanka as an example. Am J Orthopsychiatry 2008;78(2):229-239
24. Bremner JD, Southwick SM, Johnson DR, et al. Childhood physical abuse and combat-related posttraumatic stress disorder in Vietnam veterans. Am J Psychiatry 1993;150(2):235-239 (Pubitemid 23046508)
25. Kulka R, Schlenger W, Fairbank J, et al. Trauma and the Vietnam war generation: report of findings from the National Vietnam Veterans Readjustment Study. New York, NY: Brunner/Mazel, 1990
26. Zaidi LY, Foy DW. Childhood abuse experiences and combat-related PTSD. J Trauma Stress 1994;7(1):33-42 (Pubitemid 24250529)
27. King DW, King LA, Foy DW, Gudanowski DM. Prewar factors in combat-related posttraumatic stress disorder: structural equation modeling with a national sample of female and male Vietnam veterans. J Consult Clin Psychol 1996;64(3):520-531 (Pubitemid 26230546)
28. Galea S, Resnick H, Ahern J, et al. Posttraumatic stress disorder in Manhattan, New York City, after the september 11th terrorist attacks. J Urban Health 2002;79(3):340-353 (Pubitemid 35014666)
29. Breslau N, Peterson EL, Schultz LR. A second look at prior trauma and the posttraumatic stress disorder effects of subsequent trauma: a prospective epidemiological study. Arch Gen Psychiatry 2008;65(4):431-437
30. Baker D, Risbrough V, Schork N. Post traumatic stress disorder: genetic and environmental risk factors. In: Lukey BJ, Tepe V, editors, Biobehavioral resilience to stress. Boca Raton: CRC Press; 2008
31. Koenen KC, Lyons MJ, Goldberg J, et al. A high risk twin study of combat-related PTSD comorbidity. Twin Res 2003;6(3):218-226 (Pubitemid 36735602)
32. Jang KL, Taylor S, Stein MB, Yamagata S. Trauma exposure and stress response: exploration of mechanisms of cause and effect. Twin Res Hum Genet 2007;10(4):564-572 (Pubitemid 47327018)
33. Koenen KC, Fu QJ, Ertel K, et al. Common genetic liability to major depression and posttraumatic stress disorder in men. J Affect Disord 2008;105(1-3):109-115 (Pubitemid 350236354)
34. Scherrer JF, Xian H, Lyons MJ, et al. Posttraumatic stress disorder; combat exposure; and nicotine dependence, alcohol dependence, and major depression in male twins. Compr Psychiatry 2008;49(3):297-304
35. Nugent NR, Amstadter AB, Koenen KC. Genetics of post-traumatic stress disorder: informing clinical conceptualizations and promoting future research. Am J Med Genet C Semin Med Genet 2008;148(2):127-132 (Pubitemid 351705129)
36. Peleg T, Shalev AY. Longitudinal studies of PTSD: overview of findings and methods. CNS Spectr 2006;11(8):589-602 (Pubitemid 44253514)
37. O'Donnell ML, Elliott P, Lau W, Creamer M. PTSD symptom trajectories: from early to chronic response. Behav Res Ther 2007;45(3):601-606 (Pubitemid 46135514)
38. Brewin CR. Risk factor effect sizes in PTSD: what this means for intervention. J Trauma Dissociation 2005;6(2):123-130 (Pubitemid 41670857)
39. Brewin CR, Andrews B, Valentine JD. Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults. J Consult Clin Psychol 2000;68(5):748-766 (Pubitemid 30809338)
40. Kremen WS, Koenen KC, Boake C, et al. Pretrauma cognitive ability and risk for posttraumatic stress disorder: a twin study. Arch Gen Psychiatry 2007;64(3):361-368 (Pubitemid 46376787)
41. Alonso J, Angermeyer MC, Bernert S, et al. 12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;109(420):28-37 (Pubitemid 38686194)
42. Zimmerman M, McGlinchey JB, Chelminski I, Young D. Diagnostic co-morbidity in 2300 psychiatric out-patients presenting for treatment evaluated with a semi-structured diagnostic interview. Psychol Med 2008;38(2):199-210 (Pubitemid 351156594)
43. Neria Y, Olfson M, Gameroff MJ, et al. Trauma exposure and posttraumatic stress disorder among primary care patients with bipolar spectrum disorder. Bipolar Disord 2008;10(4):503-510 (Pubitemid 351619166)
44. Perkonigg A, Pfister H, Stein MB, et al. Longitudinal course of posttraumatic stress disorder and posttraumatic stress disorder symptoms in a community sample of adolescents and young adults. Am J Psychiatry 2005;162(7):1320-1327 (Pubitemid 40905583)
45. Sareen J, Cox BJ, Goodwin RD, G JGA. Co-occurrence of posttraumatic stress disorder with positive psychotic symptoms in a nationally representative sample. J Trauma Stress 2005;18(4):313-322 (Pubitemid 46421979)
46. Koenen KC, Moffitt TE, Caspi A, et al. The developmental mental-disorder histories of adults with posttraumatic stress disorder: a prospective longitudinal birth cohort study. J Abnorm Psychol 2008;117(2):460-466 (Pubitemid 351766764)
47. Druss BG, Hwang I, Petukhova M, et al. Impairment in role functioning in mental and chronic medical disorders in the United States: results from the national comorbidity survey replication. Mol Psychiatry 2008 DOI: 10.1038/mp.2008.13. Available at http://www.nature.com
48. Alonso J, Angermeyer MC, Bernert S, et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;109(420):38-46 (Pubitemid 38686195)
49. Brunello N, Davidson JR, Deahl M, et al. Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology 2001;43(3):150-162 (Pubitemid 32268586)
50. Sareen J, Houlahan T, Cox BJ, Asmundson GJ. Anxiety disorders associated with suicidal ideation and suicide attempts in the national comorbidity survey. J Nerv Ment Dis 2005;193(7):450-454 (Pubitemid 40967749)
51. Sareen J, Cox BJ, Stein MB, et al. Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample. Psychosom Med 2007;69(3):242-248 (Pubitemid 46653076)
52. Stein MB, Walker JR, Hazen AL, Forde DR. Full and partial posttraumatic stress disorder: findings from a community survey. Am J Psychiatry 1997;154(8):1114-1119 (Pubitemid 27328828)
53. Marshall RD, Olfson M, Hellman F, et al. Comorbidity, impairment, and suicidality in subthreshold PTSD. Am J Psychiatry 2001;158(9):1467-1473 (Pubitemid 32847247)
54. Pitman RK, Orr SP, Shalev AY, et al. Psychophysiological alterations in post-traumatic stress disorder. Semin Clin Neuropsychiatry 1999;4(4):234-241
55. Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003;417:38-50 (Pubitemid 37152322)
56. Brewin CR, Dalgleish T, Joseph S. A dual representation theory of posttraumatic stress disorder. Psychol Rev 1996;103(4):670-686 (Pubitemid 126664718)
57. Agid Y, Buzsaki G, Diamond DM, et al. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 2007;6(3):189-201
58. Litz BT. Early intervention for trauma: where are we and where do we need to go? A commentary. J Trauma Stress 2008;21(6):503-506
59. Forbes D, Creamer M, Phelps A, et al. Australian guidelines for the treatment of adults with acute stress disorder and post-traumatic stress disorder. Aust NZ J Psychiatry 2007;41(8):637-648 (Pubitemid 47189814)
60. National Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence. Post-traumatic stress disorder: the management of PTSD in adults and children in primary and secondary care. London: published by Gaskell and the British Psychological Society, 2005 •• This monograph provides a comprehensive review of psychotherapeutic and pharmacologic PTSD treatment studies.
61. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2006;Issue 1. Art. No.: CD002795. DOI: 10.1002/14651858. CD002795.pub2
62. Institute of Medicine (IOM). Committee on Treatment of Posttraumatic Stress Disorder. Treatment of posttraumatic stress disorder: an assessment of the evidence. Washington, D.C.: National Academies Press, 2008 •• This monograph provides a comprehensive review of psychotherapeutic and pharmacologic PTSD treatment studies.
63. Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. department of veterans affairs: diagnostic- and symptom-guided drug selection. J Clin Psychiatry 2008;69(6):959-965 (Pubitemid 351944949)
64. Harpaz-Rotem I, Rosenheck RA, Mohamed S, Desai RA. Pharmacologic treatment of posttraumatic stress disorder among privately insured Americans. Psychiatr Serv 2008;59(10):1184-1190
65. McCrone P, Knapp M, Cawkill P. Posttraumatic stress disorder (PTSD) in the Armed Forces: health economic considerations. J Trauma Stress 2003;16(5):519-522 (Pubitemid 37280234)
66. McCrone P, Weich S. The costs of mental health care: paucity of measurement. In: Tansella M, Thornicroft G, editors, Mental health outcome measures. 2nd edition. London: Gaskell; 2001. p. ix, 325
67. Alderman CP, McCarthy LC, Marwood AC. Pharmacotherapy for post-traumatic stress disorder. Expert Rev Clin Pharmacol 2009;2(1):77-86
68. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000;283(14):1837-1844 (Pubitemid 30207620)
69. Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001;158(12):1974-1981 (Pubitemid 33104101)
70. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001;158(12):1982-1988 (Pubitemid 33104102)
71. Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62(11):860-868 (Pubitemid 33131172)
72. Friedman MJ, Marmar CR, Baker DG, et al. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a department of veterans affairs setting. J Clin Psychiatry 2007;68(5):711-720 (Pubitemid 46841854)
73. Simon NM, Connor KM, Lang AJ, et al. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry 2008;69(3):400-405 (Pubitemid 351549392)
74. Katz RJ, Lott MH, Arbus P, et al. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety 1994;1(4):169-174
75. Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991;179(6):366-370
76. Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res 1988;24(2):149-155 (Pubitemid 18147311)
77. Boscarino JA. Psychobiologic predictors of disease mortality after psychological trauma: implications for research and clinical surveillance. J Nerv Ment Dis 2008;196(2):100-107 (Pubitemid 351253421)
78. Baker DG, Geracioti TDJ, Kasckow JW, et al. Cytokines and post traumatic stress disorder. In: Kronfol Z, editor, Cytokines and mental health. Boston; London: Kluwer Academic Publishers; 2003
79. Heppner PS, Crawford EF, Haji UA, et al. The association of posttraumatic stress disorder and metabolic syndrome: a study of increased health risk in veterans. BMC Med 2009;7(1):1
80. Padala PR, Madison J, Monnahan M, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol 2006;21(5):275-280 (Pubitemid 44162479)
81. Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005;57(5):474-479 (Pubitemid 40311981)
82. Reich DB, Winternitz S, Hennen J, et al. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry 2004;65(12):1601-1606
83. Hamner MB, Faldowski RA, Ulmer HG, et al. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 2003;18(1):1-8 (Pubitemid 36127054)
84. Monnelly EP, Ciraulo DA, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003;23(2):193-196 (Pubitemid 36368797)
85. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159(10):1777-1779
86. Butterfield MI, Becker ME, Connor KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001;16(4):197-203 (Pubitemid 32612517)
87. Rothbaum BO, Killeen TK, Davidson JR, et al. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry 2008;69(4):520-525 (Pubitemid 351792325)
88. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003;28(6):1186-1197
89. Davis LL, Davidson JR, Ward LC, et al. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol 2008;28(1):84-88
90. Davidson JR, Brady K, Mellman TA, et al. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007;27(1):85-88 (Pubitemid 46105772)
91. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999;45(9):1226-1229 (Pubitemid 29236566)
92. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68(2):201-206 (Pubitemid 46362640)
93. Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008;63(6):629-632 (Pubitemid 351273194)
94. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003;160(2):371-373 (Pubitemid 41110467)
95. Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007;61(8):928-934 (Pubitemid 46505008)
96. Neylan TC, Lenoci M, Samuelson KW, et al. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 2006;163(12):2186-2188 (Pubitemid 46114243)
97. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990;51(6):236-238 (Pubitemid 20209219)
98. Gelpin E, Bonne O, Peri T, et al. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996;57(9):390-394 (Pubitemid 26321989)
99. Davidson J, Rothbaum BO, Tucker P, et al. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 2006;26(3):259-267 (Pubitemid 43804617)
100. Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006;63(10):1158-1165 (Pubitemid 44498394)
101. Rothbaum BO, Cahill SP, Foa EB, et al. Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress 2006;19(5):625-638 (Pubitemid 46424377)
102. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 2006;60(4):369-375 (Pubitemid 44215855)
103. Foa EB. Psychosocial therapy for posttraumatic stress disorder. J Clin Psychiatry 2006;67(Suppl 2):40-45 (Pubitemid 43268188)
104. Rothbaum BO, Davis M. Applying learning principles to the treatment of post-trauma reactions. Ann NY Acad Sci 2003;1008(1):112-121 (Pubitemid 38265155)
105. Quirk GJ, Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2007;33(1):56 •• This reference provides a review of neural mechanisms of extinction learning and retrieval.
106. Henry M, Fishman JR, Youngner SJ. Propranolol and the prevention of post-traumatic stress disorder: is it wrong to erase the "sting" of bad memories? Am J Bioeth 2007;7(9):12-20
107. McGaugh JL, Roozendaal B. Role of adrenal stress hormones in forming lasting memories in the brain. Curr Opin Neurobiol 2002;12(2):205-210 (Pubitemid 34518341)
108. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008;455(7215):894-902
109. Krishnan V, Han MH, Mazei-Robison M, et al. AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol Psychiatry 2008;64(8):691-700
110. Krishnan V, Han MH, Graham DL, et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007;131(2):391-404 (Pubitemid 47576141)
111. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301(5631):386-389 (Pubitemid 36877077)
112. Eley TC, Sugden K, Corsico A, et al. Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol Psychiatry 2004;9(10):908-915 (Pubitemid 39381955)
113. Kaufman J, Yang BZ, Douglas-Palumberi H, et al. Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci USA 2004;101(49):17316-17321 (Pubitemid 39627817)
114. Grabe HJ, Lange M, Wolff B, et al. Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. Mol Psychiatry 2005;10(2):220-224 (Pubitemid 40188517)
115. Kendler KS, Kuhn JW, Vittum J, et al. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 2005;62(5):529-535 (Pubitemid 40628882)
116. Gillespie NA, Whitfield JB, Williams B, et al. The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. Psychol Med 2005;35(1):101-111 (Pubitemid 40201920)
117. Hariri AR, Drabant EM, Munoz KE, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 2005;62(2):146-152 (Pubitemid 40189130)
118. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274(5292):1527-1531 (Pubitemid 26403928)
119. Garpenstrand H, Annas P, Ekblom J, et al. Human fear conditioning is related to dopaminergic and serotonergic biological markers. Behav Neurosci 2001;115(2):358-364 (Pubitemid 32378165)
120. Stein MB, Campbell-Sills L, Gelernter J. Genetic variation in 5HTTLPR is associated with emotional resilience. Am J Med Genet B Neuropsychiatr Genet 2009 DOI://10.1002/ajmg.b.30916
121. Lee JLC, Milton AL, Everitt BJ. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J Neurosci 2006;26(39):10051- 10056 (Pubitemid 44477166)
122. Kilpatrick DG, Koenen KC, Ruggiero KJ, et al. The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults. Am J Psychiatry 2007;164(11):1693-1699 (Pubitemid 350205346)
123. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87(3):873-904 (Pubitemid 47086281)
124. Schulkin J, Morgan MA, Rosen JB. A neuroendocrine mechanism for sustaining fear. Trends Neurosci 2005;28(12):629-635 (Pubitemid 41654386)
125. Yehuda R, Halligan SL, Grossman R, et al. The cortisol and glucocorticoid receptor response to low dose dexamethasone administration in aging combat veterans and holocaust survivors with and without posttraumatic stress disorder. Biol Psychiatry 2002;52(5):393-403 (Pubitemid 35266730)
126. Yehuda R. Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. Ann NY Acad Sci 2006;1071:137-166 (Pubitemid 44126726)
127. Shalev AY, Videlock EJ, Peleg T, et al. Stress hormones and post-traumatic stress disorder in civilian trauma victims: a longitudinal study. Part I: HPA axis responses. Int J Neuropsychopharmacol 2008;11(3):365-372
128. Baker DG, Ekhator NN, Kasckow JW, et al. Increased basal serial cerebrospinal fluid cortisol in combat veterans with posttraumatic stress disorder. Am J Psychiatry 2005;162(5):992-994 (Pubitemid 40676214)
129. Cohen H, Zohar J, Gidron Y, et al. Blunted HPA axis response to stress influences susceptibility to posttraumatic stress response in rats. Biol Psychiatry 2006;59(12):1208-1218 (Pubitemid 43912551)
130. Olff M, Güzelcan Y, de Vries G-J, et al. HPA- and HPT-axis alterations in chronic posttraumatic stress disorder. Psychoneuroendocrinology 2006;31(10):1220 (Pubitemid 44803088)
131. Yang YL, Chao PK, Lu KT. Systemic and intra-amygdala administration of glucocorticoid agonist and antagonist modulate extinction of conditioned fear. Neuropsychopharmacology 2006;31:912-924
132. de Quervain DJF, Margraf J. Glucocorticoids for the treatment of post-traumatic stress disorder and phobias: a novel therapeutic approach. Eur J Pharmacol 2008;583(2-3):365
133. Schelling G, Kilger E, Roozendaal B, et al. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol Psychiatry 2004;55(6):627 (Pubitemid 38315037)
134. Aerni A, Traber R, Hock C, et al. Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry 2004;161(8):1488-1490 (Pubitemid 38989105)
135. Cai W-H, Blundell J, Han J, et al. Postreactivation glucocorticoids impair recall of established fear memory. J Neurosci 2006;26(37):9560-9566 (Pubitemid 44396869)
136. Joseph M. Andreano LC. Glucocorticoid release and memory consolidation in men and women. Psychol Sci 2006;17(6):466-470 (Pubitemid 43855788)
137. Roozendaal B. Systems mediating acute glucocorticoid effects on memory consolidation and retrieval. Prog Neuro Psychopharmacol Biol Psychiatry 2003;27(8):1213 (Pubitemid 37501027)
138. Flores BH, Kenna H, Keller J, et al. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2005;31(3):628
139. Young AH, Gallagher P, Watson S, et al. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004;29(8):1538 (Pubitemid 38982247)
140. Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry 2006;12(2):120 (Pubitemid 46160979)
141. Walker DL, Davis M. The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 2002;71(3):379-392 (Pubitemid 34117707)
142. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008;63(12):1118
143. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008;63(6):544-549
144. Guastella AJ, Lovibond PF, Dadds MR, et al. A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behav Res Ther 2007;45(4):663-672 (Pubitemid 46282625)
145. Guastella AJ, Dadds MR, Lovibond PF, et al. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res 2007;41(6):466-471 (Pubitemid 46227445)
146. Craske MG, Kircanski K, Zelikowsky M, et al. Optimizing inhibitory learning during exposure therapy. Behav Res Ther 2008;46(1):5
147. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-864 (Pubitemid 44188478)
148. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47(4):351-354 (Pubitemid 30109248)
149. Parwani A, Weiler M, Blaxton T, et al. The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology 2005;183(3):265-274 (Pubitemid 41660411)
150. Tsai GE. Searching for rational anti N-methyl-D-aspartate treatment for depression. Arch Gen Psychiatry 2007;64(9):1099-1100 (Pubitemid 47360860)
151. Layton ME, Kelly MJ 3rd, Rodzinak KJ. Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. Curr Top Med Chem 2006;6(7):697-709
152. Zushida K, Sakurai M, Wada K, Sekiguchi M. Facilitation of extinction learning for contextual fear memory by PEPA: a potentiator of AMPA receptors. J Neurosci 2007;27(1):158-166 (Pubitemid 46089970)
153. Nordquist R, Steckler T, Wettstein J, et al. Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety. Psychopharmacology 2008;199(3):389
154. Schoepp DD, Wright RA, Levine LR, et al. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003;6(3):189-197 (Pubitemid 37210425)
155. Helton DR, Tizzano JP, Monn JA, et al. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 1998;284(2):651-660 (Pubitemid 28086655)
156. Scaccianoce S, Matrisciano F, Del Bianco P, et al. Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic- pituitary-adrenocortical axis. Neuropharmacology 2003;44(5):555-561 (Pubitemid 36369136)
157. Grillon C, Cordova J, Levine L, Morgan IIIC. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology 2003;168(4):446 (Pubitemid 36994028)
158. Muly CE, Mania I, Guo J, Rainnie DG. Group II metabotropic glutamate receptors in anxiety circuitry: correspondence of physiological response and subcellular distribution. J Comp Neurol 2007;505(6):682-700 (Pubitemid 350247133)
159. Dunayevich E, Erickson J, Levine L, et al. Efficacy and tolerability of an mGlu2//3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2007;33(7):1603
160. Palucha A, Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007;115(1):116 (Pubitemid 46992810)
161. Pecknold JC, McClure DJ, Appeltauer L, et al. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982;2(2):129-133
162. Henry SA, Lehmann-Masten V, Gasparini F, et al. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002;43(8):1199-1209 (Pubitemid 36084431)
163. Berry-Kravis EM, Hessl D, Coffey S, et al. A pilot open-label single-dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009
164. Cahill L, Babinsky R, Markowitsch HJ, McGaugh JL. The amygdala and emotional memory. Nature 1995;377(6547):295-296
165. Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002;51(2):189-192 (Pubitemid 34127909)
166. Vaiva G, Ducrocq F, Jezequel K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003;54(9):947-949 (Pubitemid 37311359)
167. Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacotherapy to prevent PTSD: results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 2007;20(6):923-932
168. Brunet A, Orr SP, Tremblay J, et al. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res 2008;42(6):503 (Pubitemid 351240920)
169. Debiec J, LeDoux JE. Noradrenergic signaling in the amygdala contributes to the reconsolidation of fear memory: treatment implications for PTSD. Ann NY Acad Sci 2006;1071:521-524 (Pubitemid 44126769)
170. Mustapic M, Pivac N, Kozaric-Kovacic D, et al. Dopamine beta-hydroxylase (DBH) activity and -1021C/T polymorphism of DBH gene in combat-related post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet 2007;144B(8):1087-1089 (Pubitemid 350207786)
171. Hamner MB, Gold PB. Plasma dopamine beta-hydroxylase activity in psychotic and non-psychotic post-traumatic stress disorder. Psychiatry Res 1998;77(3):175-181 (Pubitemid 28157269)
172. Southwick SM, Krystal JH, Bremner JD, et al. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1997;54(8):749-758 (Pubitemid 27344103)
173. Sajdyk TJ, Johnson PL, Leitermann RJ, et al. Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J Neurosci 2008;28(4):893-903 (Pubitemid 351159007)
174. Baker DG, West SA, Nicholson WE, et al. Serial CSF corticotropin- releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 1999;156(4):585-588 (Pubitemid 29162980)
175. Gutman AR, Yang Y, Ressler KJ, Davis M. The role of Neuropeptide Y in the expression and extinction of fear-potentiated startle. J Neurosci 2008;28(48):12682-12690
176. Sajdyk TJ, Vandergriff MG, Gehlert DR. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 1999;368(2-3):143 (Pubitemid 29117135)
177. Yang L, Scott KA, Hyun J, et al. Role of dorsomedial hypothalamic Neuropeptide Y in modulating food intake and energy balance. J Neurosci 2009;29(1):179-190
178. Bremner JD, Licinio J, Darnell A, et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 1997;154(5):624-629 (Pubitemid 27197594)
179. Sautter FJ, Bissette G, Wiley J, et al. Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry 2003;54(12):1382-1388 (Pubitemid 37522162)
180. Gilbertson MW, Shenton ME, Ciszewski A, et al. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci 2002;5(11):1242-1247 (Pubitemid 35247185)
181. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999;160(1):1-12 (Pubitemid 29044562)
182. Grigoriadis DE. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 2005;9(4):651-684
183. Valdez GR, Zorrilla EP, Koob GF. Homeostasis within the corticotropin-releasing factor system via CRF2 receptor activation: a novel approach for the treatment of anxiety. Drug Dev Res 2005;65(4):205-215 (Pubitemid 43017104)
184. Dyck B, Grigoriadis DE, Gross RS, et al. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. J Med Chem 2005;48(12):4100-4110 (Pubitemid 40800618)
185. Zobel AW, Nickel T, Kunzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000;34(3):171-181 (Pubitemid 30364916)
186. Binneman B, Feltner D, Kolluri S, et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a Selective CRH1 Antagonist) in the treatment of major depression. Am J Psychiatry 2008;165(5):617-620
187. Insel TR, Shapiro LE. Oxytocin receptor distribution reflects social organization in monogamous and polygamous voles. Proc Natl Acad Sci USA 1992;89(13):5981-5985
188. Kirsch P, Esslinger C, Chen Q, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 2005;25(49):11489-11493 (Pubitemid 43083720)
189. Domes G, Heinrichs M, Gläscher J, et al. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 2007;62(10):1187-1190 (Pubitemid 350029722)
190. Petrovic P, Kalisch R, Singer T, Dolan RJ. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J Neurosci 2008;28(26):6607-6615
191. Bale TL, Davis AM, Auger AP, et al. CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. J Neurosci 2001;21(7):2546-2552 (Pubitemid 32240551)
192. Kovács GL, Vécsei L, Telegdy G. Opposite action of oxytocin to vasopressin in passive avoidance behavior in rats. Physiol Behav 1978;20(6):801 (Pubitemid 8372948)
193. Pitman RK, Orr SP, Lasko NB. Effects of intranasal vasopressin and oxytocin on physiologic responding during personal combat imagery in Vietnam veterans with posttraumatic stress disorder. Psychiatry Res 1993;48(2):107 (Pubitemid 23258246)
194. Seifer DB, Sandberg EC, Ueland K, Sladen RN. Water intoxication and hyponatremic encephalopathy from the use of an oxytocin nasal spray. A case report. J Reprod Med 1985;30(3):225-228 (Pubitemid 15090387)
195. Viveros MP, Marco EM, Llorente R, Lopez-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007;2007:52908 (Pubitemid 351201245)
196. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002;418(6897):530 (Pubitemid 34851398)
197. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2004;30(3):516
198. Pamplona F, Prediger R, Pandolfo P, Takahashi R. The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology 2006;188(4):641 (Pubitemid 46758971)
199. Lin H-C, Mao S-C, Chen P-S, Gean P-W. Chronic cannabinoid administration in vivo compromises extinction of fear memory. Learn Mem 2008;15(12):876-884
200. Zohar J, Amital D, Miodownik C, et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 2002;22(2):190-195 (Pubitemid 34289394)
201. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6(8):591-602 (Pubitemid 41059334)
202. de Boer AG, Gaillard PJ. Strategies to improve drug delivery across the blood-brain barrier. Clin Pharmacokinet 2007;46(7):553-576 (Pubitemid 47025357)
203. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007;47:323-355 (Pubitemid 46272133)
204. Thoeringer CK, Wultsch T, Shahbazian A, et al. Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress. Psychoneuroendocrinology 2007;32(8-10):1028-1040 (Pubitemid 350086821)
205. Hoge CW, Castro CA, Messer SC, et al. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 2004;351(1):13-22 (Pubitemid 38857243)
206. Milliken CS, Auchterlonie JL, Hoge CW. Longitudinal assessment of mental health problems among active and reserve component soldiers returning from the Iraq war. JAMA 2007;298(18):2141-2148 (Pubitemid 350106652)